Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population (vol 189, pg 689, 2021)

被引：0

作者：

De Laurentiis, Michelino ^{[1
]}

Borstnar, Simona ^{[2
]}

Campone, Mario ^{[3
]}

Warner, Ellen ^{[4
]}

Bofill, Javier Salvador ^{[5
]}

Jacot, William ^{[6
]}

Dent, Susan ^{[7
,17
]}

Martin, Miguel ^{[8
]}

Ring, Alistair ^{[9
]}

Cottu, Paul ^{[10
]}

Lu, Janice ^{[11
]}

Ciruelos, Eva ^{[12
]}

Azim, Hamdy A. ^{[13
]}

Chatterjee, Sanjoy ^{[14
]}

Zhou, Katie ^{[15
]}

Wu, Jiwen ^{[15
]}

Menon-Singh, Lakshmi ^{[15
]}

Zamagni, Claudio ^{[16
]}

机构：

[1] Ist Nazl Tumori IRCCS Fdn Pascale, Dept Breast & Thorac Oncol Director, Div Breast Med Oncol, Naples, Italy

[2] Inst Oncol Ljubljana, Ljubljana, Slovenia

[3] Western Canc Inst, Nantes, France

[4] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada

[5] Virgen Rocio Univ Hosp, Biomed Inst, Seville, Spain

[6] Montpellier Canc Inst, Montpellier, France

[7] Ottawa Hosp, Ctr Canc, Ottawa, ON, Canada

[8] Univ Complutense, CIBERONC, GEICAM, Gregorio Maranon Gen Univ Hosp, Madrid, Spain

[9] Royal Marsden Hosp NHS Fdn Trust, Sutton, Surrey, England

[10] Curie Inst, Paris, France

[11] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA

[12] Univ Hosp 12 Octubre, Clara Campal Comprehens Canc Ctr, HM CIOCC, Madrid, Spain

[13] Cairo Univ, Fac Med, Cairo, Egypt

[14] Tata Med Ctr, Kolkata, India

[15] Novartis Pharmaceut, E Hanover, NJ USA

[16] Azienda Ospedaliero Univ Bologna, Bologna, Italy

[17] Duke Univ, Sch Med, Duke Canc Inst, Durham, NC USA

来源：

BREAST CANCER RESEARCH AND TREATMENT | 2022年 / 191卷 / 01期

关键词：

D O I：

10.1007/s10549-021-06374-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：223 / 224

页数：2

共 50 条

[21] Ribociclib (RIBO) plus letrozole (LET) in patients (pts) with hormone receptorpositive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary results from the phase 3b CompLEEment-1 trial.
DeLaurentiis, Michelino
Neven, Patrick
Jerusalem, Guy Heinrich Maria
Bachelot, Thomas Denis
Jacot, William
Dent, Susan Faye
Colleoni, Marco
Prat, Aleix
Martin, Miguel
Ring, Alistair E.
Cottu, Paul H.
Lu, Janice M.
Azim, Hamdy A.
Zhou, Katie
Wu, Jiwen
Zarate, Juan Pablo
Zamagni, Claudio
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[22] Ribociclib (RIBO) plus letrozole (LET) in older patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Preliminary subgroup results from the phase 3b CompLEEment-1 trial
Ring, A.
Borstnar, S.
Ferreira, A.
Azim, H. A.
Cottu, P.
Lu, J.
Martin, M.
Zamagni, C.
Beck, J. T.
Zhou, K.
Wu, J.
Menon, L.
De laurentiis, M.
CANCER RESEARCH, 2019, 79 (04)
[23] RIBOCICLIB (RIB) plus LETROZOLE (LET) IN OLDER PATIENTS (PTS) WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC): SUBGROUP RESULTS FROM THE PHASE 3B COMPLEEMENT-1 TRIAL
De Laurentiis, Michelino
Campone, Mario
Alba Conejo, Emilio
Tanner, Minna
Egle, Daniel
Papai, Zsuzsanna
Prat Aparicio, Aleix
Dent, Susan
Warner, Ellen
Ankrah, Nii
Wu, Jiwen
Zhou, Katie
Borstnar, Simona
BREAST, 2019, 48 : S46 - S47
[24] Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group (vol 19, pg 2596, 2001)
Mouridsen
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (13) : 3302 - 3302
[25] Palbociclib-letrozole as first-line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study
Takahashi, Masato
Masuda, Norikazu
Nishimura, Reiki
Inoue, Kenichi
Ohno, Shinji
Iwata, Hiroji
Hashigaki, Satoshi
Muramatsu, Yasuaki
Umeyama, Yoshiko
Toi, Masakazu
CANCER MEDICINE, 2020, 9 (14): : 4929 - 4940
[26] Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group
Illiger, HJ
STRAHLENTHERAPIE UND ONKOLOGIE, 2002, 178 (02) : 111 - 113
[27] Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer:: Results of a phase III study of the international letrozole breast cancer group
Mouridsen, H
Gershanovich, M
Sun, Y
Pérez-Carrión, R
Boni, C
Monnier, A
Apffelstaedt, J
Smith, R
Sleeboom, HP
Jänicke, F
Pluzanska, A
Dank, M
Becquart, D
Bapsy, PP
Salminen, E
Snyder, R
Lassus, M
Verbeek, JA
Staffler, B
Chaudri-Ross, HA
Dugan, M
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) : 2596 - 2606
[28] Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer (vol 29, pg 1541, 2018)
Hortobagyi, G. N.
Stemmer, S. M.
Burris, H. A.
Yap, Y. S.
Sonke, G. S.
Paluch-Shimon, S.
Campone, M.
Petrakova, K.
Blackwell, K. L.
Winer, E. P.
Janni, W.
Verma, S.
Conte, P.
Arteaga, C. L.
Cameron, D. A.
Mondal, S.
Su, F.
Miller, M.
Elmeliegy, M.
Germa, C.
O'Shaughnessy, J.
ANNALS OF ONCOLOGY, 2019, 30 (11) : 1842 - 1842
[29] Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
Hortobagyi, G. N.
Stemmer, S. M.
Burris, H. A.
Yap, Y. S.
Sonke, C. S.
Paluch-Shimon, S.
Campone, M.
Petrakova, K.
Blackwell, K. L.
Winer, E. P.
Janni, W.
Verma, S.
Conte, P.
Arteaga, C. L.
Cameron, D. A.
Mondal, S.
Su, F.
Miller, M.
Elmeliegy, M.
Germa, C.
O'Shaughnessy, J.
ANNALS OF ONCOLOGY, 2018, 29 (07) : 1541 - 1547
[30] CompLEEment-1: phase 3b study of ribociclib 1 letrozole for the treatment of hormone receptor-positive (HR1), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in patients with no prior endocrine therapy (ET) for ABC
Zamagni, C.
Martin, M.
Ring, A.
Cottu, P.
Zhou, K.
Wu, J.
Zarate, J. P.
De Laurentiis, M.
ANNALS OF ONCOLOGY, 2017, 28

← 1 2 3 4 5 →